Pfizer sues Aurobindo, Dr Reddy’s over generic version of cancer drug

Our Bureau. Hyderabad | Updated on November 17, 2020 Published on November 17, 2020

Pfizer Inc has filed a petition in a US court against Aurobindo Pharma Ltd and Dr Reddy’s Laboratories Ltd on their alleged separate plans to launch generic versions of its drug Ibrance (palbociclib) before expiration of its patent.

The drug is indicated in the treatment of certain types of cancer. It clocked about $5 billion revenue in globally for Pfizer, according to agency reports citing company data.

The  companies assert the invalidity and non-infringement of two composition-of-matter patents and a method-of-use patent covering palbociclib, each of which expires in 2023, according to the annual report.

Pfizer contented that the Hyderabad-based drug makers had filed abbreviated new drug application (ANDA) with the US drug regulator for approval for the generic of Ibrance prior to the expiry of the patent.

When contacted, Dr Reddy's Laboratories declined to comment. Aurobindo, too, has not come out with a statement  on the matter yet.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on November 17, 2020
This article is closed for comments.
Please Email the Editor